GENEVA--(BUSINESS WIRE)--Relief Therapeutics a Swiss-based, privately owned startup company announced today an in-licensing agreement from Merck Serono, the biopharmaceutical business of Merck, Darmstadt, Germany, giving Relief Therapeutics the worldwide exclusive rights to develop and commercialize atexakin alfa. Financial terms were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
